F. Angeli

Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.

C. Macrae, T. Ripoll-Vera, Pablo García-Pavía, 2024, ESC Heart Failure.

International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction.

E. Cariou, Ben Ebede, Pablo García-Pavía, 2024, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings.

P. García-Pavía, M. Fiuzat, I. Lousada, 2024, Advances in therapy.

REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNA-Related Dilated Cardiomyopathy

R. Barriales-Villa, R. Gottlieb, Pablo García-Pavía, 2024, Circulation. Heart failure.